Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Androgen receptor mutations for precision medicine in prostate cancer
Masaki Shiota, Shusuke Akamatsu, Shigehiro Tsukahara, et al.
Endocrine Related Cancer (2022) Vol. 29, Iss. 10, pp. R143-R155
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
Weiguo Xiang, Lijie Zhao, Xin Han, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 18, pp. 13280-13303
Open Access | Times Cited: 29
Androgen receptor cofactors: A potential role in understanding prostate cancer
Xiang Li, Haojun Xiong, Xingzhu Mou, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116338-116338
Open Access | Times Cited: 6
Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting
T. Pejcic, Zoran Todorović, Siniša Đurašević, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2939-2939
Open Access | Times Cited: 13
Prostate Cancer and the Mevalonate Pathway
Patricia Guerrero-Ochoa, Sergio Rodríguez-Zapater, Alberto Anel, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2152-2152
Open Access | Times Cited: 5
The bioactivity of atraric acid as an inducer of cellular senescence in prostate cancer cells is retained by lipophilic derivatives
Aria Baniahmad, Golnaz Atri Roozbahani, Manfred Jung, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications
Daniël J. Vis, Sander Palit, Marie Corradi, et al.
Genome Medicine (2025) Vol. 17, Iss. 1
Open Access
Platelets, chromogranin A and C-reactive protein predict therapy failure of metastatic hormone-sensitive prostate cancer while miR-375 outperforms PSA in stratifying castration-resistant prostate cancer
Eva Szczyrbová, Radka Spurná, Kateřina Holá, et al.
Journal of Molecular Diagnostics (2025)
Closed Access
Current opinions invited review: testosterone and transgender medicine
Jinghang Luo, Rita Upreti
Current Opinion in Endocrinology Diabetes and Obesity (2025)
Closed Access
Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
Paulina J. Dziubańska-Kusibab, Ekaterina Nevedomskaya, Bernard Haendler
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 705-705
Open Access | Times Cited: 4
Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator–activated receptor promotes enzalutamide resistance in prostate cancer
Masaki Shiota, Miho Ushijima, Shigehiro Tsukahara, et al.
Free Radical Biology and Medicine (2024) Vol. 221, pp. 81-88
Open Access | Times Cited: 4
Discovery of N-(1,2,4-Thiadiazol-5-yl)benzo[b]oxepine-4-carboxamide Derivatives as Novel Antiresistance Androgen Receptor Antagonists
Jianing Liao, Jinbiao Liao, Ying Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Biological Activity and Cell Cycle Effects of Natural Extract Kaempferol on Androgen-dependent Prostate Cancer Cells
Peng Mei-kang, Tao Chen, Hui-Liu Peng
Pharmacognosy Magazine (2025)
Closed Access
Androgen receptor and estrogen receptor variants in prostate and breast cancers
José C. Valentín López, Carol A. Lange, Scott M. Dehm
The Journal of Steroid Biochemistry and Molecular Biology (2024) Vol. 241, pp. 106522-106522
Closed Access | Times Cited: 3
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
Eva Chrenková, Hana Študentová, Kateřina Holá, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Implication of androgen receptor gene dysfunction in human Müllerian duct anomalies
Lin Li, Shuya Chen, Shenghui Li, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology (2024) Vol. 294, pp. 198-205
Closed Access | Times Cited: 2
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration
Zeynep Büşra Zengin, Nicholas Henderson, Joseph J. Park, et al.
Prostate Cancer and Prostatic Diseases (2024)
Open Access | Times Cited: 2
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
Carly D. Miller, Pornlada Likasitwatanakul, Eamon Toye, et al.
Expert Review of Anticancer Therapy (2024)
Closed Access | Times Cited: 2
Prostate Cancer: Pathophysiology, Pathology and Therapy
Vassiliki Tzelepi
Cancers (2022) Vol. 15, Iss. 1, pp. 281-281
Open Access | Times Cited: 10
The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer
Liuxun Li, Jiangli Xu
Clinical & Translational Oncology (2022) Vol. 25, Iss. 2, pp. 352-363
Open Access | Times Cited: 9
Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective
Lokman Varışlı, VEYSEL TOLAN, JIYAN H. CEN, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2022) Vol. 30, Iss. 3, pp. 137-155
Open Access | Times Cited: 9
Let’s Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer
Tina Petrić, Maja Sabol
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5293-5293
Open Access | Times Cited: 5
Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide
Takashi Matsuoka, Aiko Sugiyama, Yoshifumi Miyawaki, et al.
Cancer Science (2023) Vol. 115, Iss. 1, pp. 283-297
Open Access | Times Cited: 3
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis
JuanJuan Yin, Asha Daryanani, Lu Fan, et al.
The Prostate (2024) Vol. 84, Iss. 11, pp. 1033-1046
Open Access
Snake venom toxins as potential therapeutic agents in the treatment of prostate cancer
Jesika Ochoa-Mosquera, Alejandro Montoya‐Gómez, Eliécer Jiménez‐Charris
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Open Access
Genomic characterization of metastatic patterns in prostate cancer using circulating tumor DNA data from the SCRUM-Japan MONSTAR SCREEN project
Masaki Shiota, Nobuaki Matsubara, Taigo Kato, et al.
The Journal of Liquid Biopsy (2024) Vol. 7, pp. 100282-100282
Open Access
Page 1 - Next Page

Scroll to top